NDAORALTABLET
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOQUEZNA (vonoprazan fumarate) is an oral potassium-competitive acid blocker (KCAB) approved in July 2024 for acid-related gastrointestinal disorders. It represents a novel mechanism distinct from proton pump inhibitors, offering faster onset and potentially superior efficacy in acid suppression. The drug is manufactured and commercialized by Phathom Pharmaceuticals.
Growth
Early-stage growth product with modest competitive pressure (30%) and emerging market presence; brand team will focus on rapid market penetration and provider education.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.
Started Oct 2023
30 enrolled
Gastric Ulcer
Career Relevance
VOQUEZNA is a nascent growth-stage product with minimal linked job openings (1), indicating early team buildout at Phathom Pharmaceuticals. Opportunities exist in entry-level roles (internships) and will expand as commercialization accelerates; career growth will track market traction and team expansion.
Intern
Worked on VOQUEZNA at Phathom Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.